Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”

Laura Ambra Nicolini(Ospedale Policlinico San Martino), Matteo Bassetti(University of Udine), Małgorzata Mikulska(Ospedale Policlinico San Martino), Alessio Signori(University of Genoa), Mauro Giacomini(University of Genoa), Federica Portunato(Ospedale Policlinico San Martino), Antonio Vena(Ospedale Policlinico San Martino), Antonio Di Biagio
Open Forum Infectious Diseases
July 29, 2020
10.1093/ofid/ofaa321
Cited by 8

Related Papers

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
|JAMA|2018|761
How to manage Pseudomonas aeruginosa infections
|Drugs in Context|2018|743
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
|The Lancet Respiratory Medicine|2014|648
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351